Skip to content
DataLookout
Menu

NCT04585490

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 8 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Lead sponsor: Maximilian Diehn to Stanford University Show 4 more changesShow less
    • Primary completion pushed from Aug 2026 to Dec 2026
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Study title shortened, about 7 words
  2. Minor Primary completion date: Apr 1, 2026 to Aug 2026
    • Study completion date: Apr 1, 2028 to Apr 2028
    v9
  3. Notable Primary completion date: Mar 2024 to Apr 1, 2026v7 Show 5 more changesShow less
    • Study completion date: Mar 2026 to Apr 1, 2028
    • Interventions: AVENIO ctDNA Surveillance Kit (Device), Carboplatin (Drug), Cisplatin (Drug), Durvalumab (Drug), Paclitaxel (Drug), Pemetrexed (Drug) to AVENIO ctDNA Surveillance Kit (Device), Carboplatin (Drug), Cisplatin (Drug), Durvalumab (Drug), Paclitaxel (Drug), Pemetrexed (Drug)…
    • Eligibility criteria expanded, about 84 words
    • Secondary endpoints revised (4)
    • Study description shortened, about 4 words
  4. Notable Lead sponsor: Joel Neal to Maximilian Diehnv5
  5. Notable Lead sponsor: Stanford University to Joel Neal
    • Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2021 to Aug 25, 2021
    • Site details revised
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Mar 2021 to Oct 2021v3
  2. Notable Primary endpoint revisedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in ctDNA Level Following Chemotherapy
Timeframe: 12 weeks

Secondary (4)

Presence of Detectable ctDNA Following Chemotherapy
Overall Survival (OS)
Progression free survival (PFS)
Durvalumab and Tremelimumab related Adverse Events (Cohort 1 MRD+ only)

Arms and interventions

Cohort 1 minimal residual disease positive (MRD+)Experimental

Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy \[carboplatin/pemetrexed\], tremelimumab (75 mg IV every 21 days) and durvalumab (1500 mg IV every 21 days), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks. Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.

Cohort 2 minimal residual disease negative (MRD )Experimental

Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab (10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.

Drugs: Durvalumab, Carboplatin, Pemetrexed, Paclitaxel, Cisplatin, Tremelimumab

Devices: AVENIO ctDNA Surveillance Kit

Sites

1 site in 1 country

  • Stanford UniversityStanford, California, United States